Abstract:Abstract High expression of the epithelial splicing regulatory protein 1 (ESRP1) is correlated with poor prognosis in estrogen receptor positive (ER+) breast cancer and acquired resistance to tamoxifen/endocrine therapies. Our previous study revealed a novel functionality of ESRP1 in metabolic dysregulation by affecting lipid metabolism and oxidoreductase processes. To further understand how metabolic programming is affected by ESRP1 expression and identify novel therapeutic targets, we developed systems biology models to explore ER+ breast cancer metabolism. Flux balance analysis (FBA) is a computational approach to predict steady-state fluxes through metabolic reactions by posing cellular “objectives” such as maximization of biomass, ATP, or minimization of reactive oxygen species that reflect selective pressures posed by the tumor microenvironment or therapeutic insults. Our custom FBA pipeline leverages transcriptomic data, mutation information, and thermodynamic constraints to generate personalized genome-scale metabolic models. In this study, 100 ESRP1-high and 100 ESRP1-low tumors from the TCGA Breast Cancer Invasive Carcinoma dataset were simulated and compared; in a secondary analysis, we simulated metabolic rerouting of tamoxifen-resistant LCC2 cells and fulvestrant-resistant LCC9 cells upon ESRP1 knockdown. The intersection of statistically significant (p < 0.05) reactions that were altered in both the TCGA and cell line contexts suggested that changes in eicosanoid metabolism and androgen and estrogen synthesis pathways are highly involved in ESRP1's role in breast cancer prognosis and resistance to endocrine therapies. Eicosanoid-utilizing enzymes are consistently altered between the ESRP1-low and high conditions; Hematopoietic prostaglandin D synthase (HPGDS), prostaglandin I2 synthase (PTDIS), and thromboxane A synthase 1 (TBXAS1) are druggable. Furthermore, reactions associated with cytosolic and lysosomal 4-hydroxy-17beta-estradiol production, catalyzed by the enzymes myeloperoxidase, lactoperoxidase, and peroxiredoxin 6, also emerged as consistently altered across the groups. The findings from this methodology have suggested novel metabolic targets to overcome tamoxifen/endocrine therapy resistance in ER+ breast cancer. Experimental validation of these targets is currently underway. Citation Format: Zachary B. Mudge, Kristof Kovacs, Melissa L. Kemp, Sunil S. Badve, Yesim Gokmen-Polar. Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3162.

Metabolic switching of estrogen-related receptor alpha in breast cancer aggression

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

The estrogen-related receptors in metabolism and cancer: newer insights

Cholesterol as an Endogenous Ligand of ERRα Promotes ERRα-Mediated Cellular Proliferation and Metabolic Target Gene Expression in Breast Cancer Cells

Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment

Estrogen-related receptor alpha (ERRα) promotes the migration, invasion and angiogenesis of breast cancer stem cell-like cells

Exploring the impact of estrogen-related receptor gamma on metabolism and disease

Caveolin-1 Down-Regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 Beta-Estradiol-Stimulated Mammary Tumorigenesis

Estrogen receptor alpha (ERα) driven trans-regulation of mitotic checkpoint complex (MCC) components affects the clinical outcome of breast cancer

High Oestrogen receptor alpha expression correlates with adverse prognosis and promotes metastasis in colorectal cancer

Computational Insights into the Interaction Mechanisms of Estrogen‐related Receptor Alpha with Endogenous Ligand Cholesterol

Abstract 3162: Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer

ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer

The Role of the Estrogen-Related Receptor Alpha (ERRa) in Hypoxia and Its Implications for Cancer Metabolism

Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines

Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators

ERα Down‐regulates Carbohydrate Responsive Element Binding Protein and Decreases Aerobic Glycolysis in Liver Cancer Cells

[Overexpression of estrogen receptor-related receptor alpha can stimulate estrogen receptor negative endometrial cancer cell proliferation].

A Key Transcription Factor in the Regulation of Energy Metabolism at an Organismic Level and a Target of the ABA/LANCL Hormone Receptor System

Insights into the Interaction Mechanisms of Estrogen-Related Receptor Alpha (errα) with Ligands Via Molecular Dynamics Simulations

Estrogen Promotes Estrogen Receptor Negative BRCA1-deficient Tumor Initiation and Progression.